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Abstract
Background Loss of muscle protein is a common feature of
wasting diseases where currently treatment is limited. This
study investigates the potential of epigallocatechin-3-gallate
(EGCg), the most abundant catechin in green tea, to reverse
the increased protein degradation and rescue the decreased
protein synthesis which leads to muscle atrophy.
Methods Studies were conducted in vitro using murine C2C12
myotubes. Increased protein degradation and reduced rates of
protein synthesis were induced by serum starvation and tu-
mour necrosis factor-α (TNF-α).
Results EGCg effectively attenuated the depression of protein
synthesis and increase in protein degradation in murine
myotubes at concentrations as low as 10 μM. Serum starva-
tion increased expression of the proteasome 20S and 19S
subunits, as well as the proteasome ‘chymotrypsin-like’ en-
zyme activity, and these were all attenuated down to basal
values in the presence of EGCg. Serum starvation did not
increase expression of the ubiquitin ligases MuRF1 and
MAFbx, but EGCg reduced their expression below basal
levels, possibly due to an increased expression of phospho
Akt (pAkt) and phospho forkhead box O3a (pFoxO3a).
Attenuation of protein degradation by EGCg was increased
in the presence of ZnSO4, suggesting an EGCg-Zn
2+ complex
may be the active species.
Conclusion The ability of EGCg to attenuate depressed pro-
tein synthesis and increase protein degradation in the
myotubule model system suggests that it may be effective in
preserving skeletal muscle mass in catabolic conditions.
Keywords Epigallocatechin gallate . Protein degradation .
Proteasome . Protein synthesis . Zinc . Tumour necrosis
factor-α
1 Introduction
Muscle atrophy plays an important role in many conditions
including cancer cachexia, chronic heart failure, chronic kid-
ney failure, AIDS and the sarcopenia of ageing. Muscle loss
results in weakness and inability to carry out normal activities,
and if severe can result in death due to respiratory impairment.
Attention has been directed towards natural products found in
certain foods as treatment of this condition. One such com-
pound is epigallocatechin-3-O-gallate (EGCg), one of the
major polyphenols found in green tea, which has potent anti-
oxidative [1], chemopreventive [2] and antitumour activity
[3]. EGCg has also been shown to attenuate wasting of skel-
etal muscle in the Lewis lung carcinoma (LLC) model of
cancer cachexia [4], as well as improve muscle function in
dystrophic mdx5Cv mice [5], and reduce contractile dysfunc-
tion in unloaded skeletal muscle [6].
Muscle atrophy results from an imbalance between the
rates of protein synthesis and degradation, usually involving
both a depression of protein synthesis and increase in degra-
dation [7]. The predominant pathway leading to myofibrillar
protein degradation is the ubiquitin-proteasome pathway [8].
The ability of EGCg to attenuate muscle wasting is probably
due to its ability to potently and specifically inhibit protea-
some activity [9] through acylation of the N-terminal threo-
nine on the β-5 (‘chymotrypsin-like’) catalytic subunit. There
have been no studies on the effect of EGCg on the depression
of protein synthesis.
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The current study examines the effect of EGCg on protein
degradation in myotubes produced by serum starvation, as
well as the depression of protein synthesis induced by tumour
necrosis factor-α (TNF-α).
2 Methods
2.1 Materials
Foetal calf serum (FCS) and horse serum (HS) were purchased
from Invitrogen (Paisley, UK). Dulbecco’s modified Eagle’s
medium (DMEM) was from PAA (Somerset, UK). L-[2,6-3H]
phenylalanine (sp.act.3.7 TBqmmol−1) was from Perkin Elmer
(Cambridge, UK). Mouse monoclonal antibodies to 20S pro-
teasome α-subunits and p42 were from Affiniti Research Prod-
ucts (Exeter, UK), and rabbit polyclonal antibodies to pFoxO3a
(S253) and FoxO3a were from Abcam (Cambridge, UK).
Tumour necrosis factor (TNF-α) and polyclonal rabbit antibody
to mouse β-actin were purchased from Sigma-Aldridge
(Dorset, UK). EGCg (Teavigo, >95 % EGCg) was from DSM
Nutritional Products Ltd (Heanor, UK). Peroxidase-conjugated
sheep antirabbit and antimouse antibodies were purchased from
GE Healthcare (Bucks, UK), as were Hybond A nitrocellulose
membranes. Enhanced chemiluminescence (ECL) develop-
ment kits were from Pierce through Thermo Fischer Scientific
(Northumberland, UK). Rabbit polyclonal antibodies to pAkt
1/2/3 (S473), mouse monoclonal antibody to Akt 1, rabbit
polyclonal antisera to atrogin-1/MAFbx and goat polyclonal
antisera to MuRF1 were purchased from Santa Cruz Biotech-
nology, Inc. (Heidelberg, Germany).
2.2 Cell culture
C2C12 myoblasts were passaged in DMEM supplemented
with 10 % FCS, 1 % glutamine and 1 % penicillin-
streptomycin under an atmosphere of 10 % CO2 in air at
37 °C. When the myoblasts reached about 80 % confluency,
they were differentiated into myotubes in DMEM containing
2 % HS, with medium changes every 2 days. Differentiation
was complete in 5–7 days, and the myotubes remained viable
for a further 4–5 days. For experiments on serum deprivation,
serum was removed after complete myotube differentiation.
There was no evidence for toxicity of EGCg to myotubes at
any of the concentrations employed in this study based on the
attachment of the myotubes to the substratum, since evenmild
toxicity causes major detachment.
2.3 Measurement of protein synthesis and degradation
in myotubes
This was performed as previously described [7]. Briefly for
protein degradation, myotubes were labelled for 24 h with
L-[2,6-3H] phenylalanine prior to experimentation, washed
extensively in PBS followed by a further incubation for 2 h
to allow degradation of short-lived proteins. Myotubes were
starved in serum-free DMEMmedia (±EGCg) for further 24 h
while negative control was maintained in 2 % horse serum at
all times. Protein degradation was determined over a 24-h
period in the presence of 2 mM non-radioactive phenylalanine
to prevent reincorporation of radioactivity. The extent of pro-
tein degradation was determined over a 24-h period from the
radioactivity released into the medium, as a fraction of the
total radioactivity (expressed as %) incorporated into the
myotubes in control cultures with serum compared with
serum-deprived cells. Protein synthesis was determined by
the incorporation of L-[2,6-3H] phenylalanine into myotubes
over a 4-h period in the presence of TNF-α (±EGCg) as
described in the figure legend. Protein synthesis was calculat-
ed as the radioactivity incorporated into acid (0.2M perchloric
acid) insoluble material as a percentage [7], compared with
control cultures with no serum.
2.4 Measurement of proteasome activity
Functional 20S proteasome activity was determined as the
“chymotrypsin-like” enzyme activity by the release of 7-
amino-4-methylcoumarin (AMC) from the fluorogenic pep-
tide succinyl-LLVY-7-AMC as previously described in detail
[10]. Activity was measured in the absence and presence of
the specific proteasome inhibitor lactacystin (10 μM) and only
lactacystin suppressible activity was considered to be protea-
some specific.
2.5 Western blotting
Samples of cytosolic protein (10–15 μg) were resolved by
10% sodium dodecylsulphate-polyacrylamide gel electropho-
resis (SDS-PAGE) as described [7], at 180 V for approximate-
ly∼1 h followed by transference onto 0.45 μm nitrocellulose
membranes, which were then blocked with 5 % Marvel in
Tris–buffered saline, pH 7.5, at 4 °C overnight. Both primary
and secondary antibodies were used at a dilution of
1:1,000. Incubation was either for 1 h at room temper-
ature, or overnight, and development was by ECL. Blots
were scanned by densitometer to quantitate differences.
2.6 Statistical analysis
Results are expressed as mean values±s.e.m for at least three
replicate experiments. Differences in mean values between
groups were determined by one-way ANOVA followed by
Tukey-Kramer multiple comparison test and p values <0.05
were considered significant.
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3 Results
As a model of muscle atrophy in vitro, the C2C12 murine
myoblast cell line was induced to differentiate into myotubes
and protein degradation was induced by serum starvation. As
shown in Fig. 1a, total protein degradation was significantly
increased by 16 h serum starvation, and further increased
slightly over the following 8 h. All subsequent assays
employed 24 h serum starvation to induce protein degrada-
tion. The increase in protein degradation achieved by serum
starvation was less than that induced by catabolic mediators
such as proteolysis-inducing factor (PIF) and angiotensin II
(Ang II) [7]. To determine the effect of EGCg on total protein
degradation, myotubes were incubated with a wide
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Fig. 1 a Effect of serum
starvation on total protein
degradation in C2C12 myotubes
after 16 and 24 h, compared with
a negative control (NC) incubated
with DMEM containing 2 % HS.
Control myotubes released
6,563.5 cpm of [3H] Phe over the
24-h period. b Effect of EGCg on
total protein degradation in C2C12
myotubes incubated in DMEM
without serum for 24 h. c Effect of
EGCg on chymotrypsin-like
enzyme activity in C2C12
myotubes starved of serum for
24 h. Differences from NC are
indicated as *p<0.05, **p<0.01
and ***p<0.001, while
differences from no serum are
shown as †p<0.05, ††p<0.01 and
†††p<0.001
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concentration range (10–150 μM) to determine the most ef-
fective concentration that could be used for subsequent studies
(Fig. 1b). While low concentrations (10 μM) of EGCg
completely attenuated the increased protein degradation in-
duced by serum starvation, higher concentrations further re-
duced basal levels of protein degradation without having a
negative effect on cell viability.
The major mechanism for protein degradation in a
number of catabolic states is the ubiquitin-proteasome
proteolytic pathway [8]. A major proteolytic enzyme in
this system is the ‘chymotrypsin-like’ enzyme activity
found on the β5 subunit of the proteasome, the activity
of which is significantly increased in the absence of
serum (Fig. 1c), and attenuated below control values
in the presence of EGCg (10 and 25 μM). Serum
starvation also increased expression of the proteasome
20S (Fig. 2a) and 19S subunits (Fig. 2b), and also
increased expression of the ubiquitin ligases MuRF1
(Fig. 2c) or MAFbx (Fig. 2d). Treatment with EGCg
reduced expression of proteasome 20S and 19S subunits
down to basal values, while reducing expression of
MuRF1 and MAFbx to below the basal levels. Expres-
sion of both pAkt (Fig. 2e) and pFoxO3a (Fig. 2f) was
increased by EGCg in a dose-related manner, while total
Akt and FoxO3a remained unchanged.
Like other polyphenols, EGCg is a chelating agent,
which may remove metal ions such as Zn2+ involved in
the increased protein degradation [11]. As shown in
Fig. 3, EGCg reduced the increased protein degradation
caused by serum deprivation (NS) to values below that
seen in the negative control with serum [NC]. In the
presence of equimolar concentrations of ZnSO4, protein deg-
radation was further decreased below that of EGCg alone,
while Zn2+ alone at this concentration had no effect on protein
degradation (Fig. 3). These results suggest that EGCg may act
in concert with Zn2+ to reduce protein degradation, possibly
through an EGCg-Zn2+ complex.
To investigate whether EGCg could reverse the de-
pression of protein synthesis induced by serum depriva-
tion, myotubes were incubated for 4 h in serum-free
media in the absence or presence of EGCg (Fig. 4).
For both concentrations of EGCg, employed protein
synthesis was significantly increased to levels above
those in the negative control.
To determine whether EGCg could also overcome the
depression of protein synthesis and increase protein
degradation caused by inflammatory cytokines,
myotubes were exposed to TNF-α (50 ng/ml) for 4 h
(Fig. 5a) or 24 h (Fig. 5b) in the absence or presence of
EGCg (10 and 50 μM). This concentration of TNF-α
was employed because previous studies [12] had indi-
cated that lower concentrations had no significant effect
on protein synthesis or degradation in murine myotubes.
The results (Fig. 5) show that both concentrations of
EGCg attenuated the depression of protein synthesis and
increased protein degradation induced by TNF-α, while
at 25 μM EGCg reduced protein degradation below
basal levels in the negative control (NC).
4 Discussion
This study shows that in murine myotubes, EGCg attenuates
both the increased protein degradation and depressed protein
synthesis induced by serum deprivation and by the inflamma-
tory cytokine TNF-α. The ability of EGCg to counteract
the increased protein degradation is linked with its abil-
ity to downregulate key components of the ubiquitin-
proteasome proteolytic pathway, including the 20S and
19S proteasome subunits, and the ubiquitin ligases (E3)
MuRF1 and MAFbx. EGCg has also been shown to
significantly reduce expression of MuRF1 and MAFbx
when upregulated by 3D clinorotation, but not by dexa-
methasone [13]. The mechanism by which EGCg
downregulates atrogene expression is unclear, but Wang
et al. [4] have shown that EGCg decreased expression
of NF-κB in muscle of tumour-bearing mice, as well as
MuRF1 and MAFbx. Activation of NF-κB has been
shown to produce profound muscle wasting through
increased expression of proteasome subunits and
MuRF1 [14]. At high concentration (100 μM), EGCg
has also been shown to stimulate phosphatidyl inositol
3-kinase (PI3K)/Akt, which in turn suppresses forkhead
box O (Fox O) activation by phosphorylation, which
prevents nuclear accumulation [15]. This study has
shown an increase in pAkt and pFoxO in serum starved
myotubes in the presence of EGCg, overexpression of
FoxO leads to extensive muscle atrophy, and increased
expression of MAFbx, but not MuRF1 [16]. The com-
bined effect of inhibiting the activity of NF-κB and
FoxO transcriptional activity during cast immobilisation
has a combined effect on reducing atrophy gene expres-
sion and atrophy [17].
The effect of EGCg on attenuating protein degrada-
tion was further enhanced in the presence of ZnSO4.
The exact mechanism for this is unclear but there have
been previous reports on the synergistic role of EGCg
and Zn+2 on inhibiting prostate cancer cell growth [18].
This study postulated an enhanced uptake of EGCg into
the cell in the presence of Zn+2. Another study has also
demonstrated an enhanced effect of EGCg and Zn on
hepatoprotectivity and attributed this to EGCg-Zn com-
plex formation [19].
In addition to attenuating protein degradation induced
by serum starvation, EGCg was also effective in atten-
uating the depression of protein synthesis in myotubes
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Fig. 2 Western blots showing expression of the 20S proteasome (a), 19S
proteasome (b) MuRF1 (c), MAFbx (d), with actin as a loading control
and pAkt (e) and pFoxo3a (f) with total Akt and FoxO3a as loading
controls in C2C12 myotubes after 24 h of serum starvation, with or
without EGCg, compared with a negative control (NC) incubated in
medium containing serum. The densitometric analysis underneath the
blots represents three separate western blots. Differences from NC are
shown as *p<0.05 and **p<0.01 while differences from no serum are
shown as †p<0.05 and ††p<0.01
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in response to TNF-α and serum starvation. We have
shown previously [20] that in this model system, de-
pression of protein synthesis by both lipopolysaccharide
(LPS) and TNF-α is due to activation of double-
stranded RNA-dependent protein kinase (PKR), with
the subsequent phosphorylation of eukaryotic initiation
factor 2(eIF2) on the α-subunit, since there is no de-
pression of protein synthesis in myotubes expressing a
catalytically inactive PKR variant. Metal ion chelating
agents such as D-myo-inositol-1,2,6-triphosphate
prevented activation of PKR and the depression of pro-
tein synthesis [11]. It is possible that EGCg attenuates
the depression of protein synthesis in response to
TNF-α via a similar mechanism involving PKR, since
EGCg is a strong metal ion chelator.
These results show that EGCg is an effective inhib-
itor of both the increased protein degradation and
depressed protein synthesis in skeletal muscle, and that
it may be useful therapeutically in the treatment of
conditions of muscle atrophy, such as cancer cachexia,
muscle disuse and sarcopenia. This study shows that
concentrations of EGCg as low as 10 μM attenuated
the depression of protein synthesis and increase in pro-
tein degradation in murine myotubes. Average doses of
EGCg that have been tested clinically range from 50 to
1,600 mg/day [21]. Maximum absorption occurs in the
small intestine, although some can take place through
the oral mucosa or the colon. The bioavailability of
EGCg is low due to sulphation, glucuronidation and
methylation in the liver, with approximately 1 % of
the ingested dose appearing in the plasma [22]. Thus
at the doses tested in humans, the mean Cmax values
ranged from 130 to 3,392 ng/ml [21], giving a maxi-
mum plasma concentration of 7.4 μM. However, single
oral doses of EGCg up to 1,600 mg/day were safe and
well tolerated, suggesting higher doses could be
employed and that a plasma concentration of 10 μM
is achievable.
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Fig. 4 Effect of EGCg on protein synthesis in serum-deprived murine
myotubes. C2C12 myotubes were incubated in the absence of serum for
4 h, and protein synthesis was measured as described in the methods
section. Differences from negative control (NC) are shown as
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Fig. 3 Effect of ZnSO4 on total protein degradation in serum-deprived
C2C12 myotubes in the presence of EGCg. Myotubes were incubated in
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